Zoller H - Search Results

1

Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety.

Blumenstein I, Shanbhag S, Langguth P, Kalra PA, Zoller H, Lim W. Blumenstein I, et al. Among authors: zoller h. Expert Opin Drug Saf. 2021 Jul;20(7):757-769. doi: 10.1080/14740338.2021.1912010. Epub 2021 May 15. Expert Opin Drug Saf. 2021. PMID: 33993818 Review.

2

Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.

Schaefer B, Würtinger P, Finkenstedt A, Braithwaite V, Viveiros A, Effenberger M, Sulzbacher I, Moschen A, Griesmacher A, Tilg H, Vogel W, Zoller H. Schaefer B, et al. Among authors: zoller h. PLoS One. 2016 Dec 1;11(12):e0167146. doi: 10.1371/journal.pone.0167146. eCollection 2016. PLoS One. 2016. PMID: 27907058 Free PMC article.

3

Iron-induced hypophosphatemia: an emerging complication.

Zoller H, Schaefer B, Glodny B. Zoller H, et al. Curr Opin Nephrol Hypertens. 2017 Jul;26(4):266-275. doi: 10.1097/MNH.0000000000000329. Curr Opin Nephrol Hypertens. 2017. PMID: 28399017 Review.

4

Letter: inconsistency in reporting of hypophosphatemia after intravenous iron.

Schaefer B, Glodny B, Wolf M, Zoller H. Schaefer B, et al. Among authors: zoller h. Aliment Pharmacol Ther. 2017 Sep;46(6):641-643. doi: 10.1111/apt.14231. Aliment Pharmacol Ther. 2017. PMID: 28805320 No abstract available.

5

Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.

Detlie TE, Lindstrøm JC, Jahnsen ME, Finnes E, Zoller H, Moum B, Jahnsen J. Detlie TE, et al. Among authors: zoller h. Aliment Pharmacol Ther. 2019 Aug;50(4):397-406. doi: 10.1111/apt.15386. Epub 2019 Jul 2. Aliment Pharmacol Ther. 2019. PMID: 31264261

6

Hypophosphatemia in children treated with ferric carboxymaltose.

Posod A, Schaefer B, Mueller T, Zoller H, Kiechl-Kohlendorfer U. Posod A, et al. Among authors: zoller h. Acta Paediatr. 2020 Jul;109(7):1491-1492. doi: 10.1111/apa.15178. Epub 2020 Jan 28. Acta Paediatr. 2020. PMID: 31955454 Free PMC article. No abstract available.

7

Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.

Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, Thomsen LL, Carpenter TO, Weber T, Brandenburg V, Zoller H. Wolf M, et al. Among authors: zoller h. JAMA. 2020 Feb 4;323(5):432-443. doi: 10.1001/jama.2019.22450. JAMA. 2020. PMID: 32016310 Free PMC article. Clinical Trial.

8

Intravenous iron supplementation therapy.

Schaefer B, Meindl E, Wagner S, Tilg H, Zoller H. Schaefer B, et al. Among authors: zoller h. Mol Aspects Med. 2020 Oct;75:100862. doi: 10.1016/j.mam.2020.100862. Epub 2020 May 19. Mol Aspects Med. 2020. PMID: 32444112 Free article. Review.

9

Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.

Schaefer B, Tobiasch M, Viveiros A, Tilg H, Kennedy NA, Wolf M, Zoller H. Schaefer B, et al. Among authors: zoller h. Br J Clin Pharmacol. 2021 May;87(5):2256-2273. doi: 10.1111/bcp.14643. Epub 2020 Dec 7. Br J Clin Pharmacol. 2021. PMID: 33188534 Free PMC article. Review.

10

Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management.

Schaefer B, Tobiasch M, Wagner S, Glodny B, Tilg H, Wolf M, Zoller H. Schaefer B, et al. Among authors: zoller h. Bone. 2022 Jan;154:116202. doi: 10.1016/j.bone.2021.116202. Epub 2021 Sep 15. Bone. 2022. PMID: 34534708 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

275 results

Search Page